CLINICAL_TRIALS ClinicalTrials.gov record update

Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00168727
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:37.413371+00:00
Published At: 2023-08-23T00:00:00+00:00
Record Updated At: 2023-08-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, Non-Hodgkin", "Lymphoma, Low-Grade"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-23"
protocolSection.identificationModule.nctId: "NCT00168727"
protocolSection.identificationModule.officialTitle: "Zevalin\u00ae (Ibritumomab Tiuxetan) Followed by Rituxan\u00ae (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.